Found: 480
Select item for more details and to access through your institution.
Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 10, p. 1449, doi. 10.1007/s40262-024-01425-9
- By:
- Publication type:
- Article
Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate.
- Published in:
- 2015
- By:
- Publication type:
- Letter to the Editor
Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?
- Published in:
- Cardiovascular Toxicology, 2018, v. 18, n. 5, p. 431, doi. 10.1007/s12012-018-9453-3
- By:
- Publication type:
- Article
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 6247, doi. 10.1007/s00432-022-04562-5
- By:
- Publication type:
- Article
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 5, p. 945, doi. 10.1007/s00432-018-2604-x
- By:
- Publication type:
- Article
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
- Published in:
- 2018
- By:
- Publication type:
- Erratum
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 10, p. 2059, doi. 10.1007/s00432-017-2445-z
- By:
- Publication type:
- Article
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 8, p. 1585, doi. 10.1007/s00432-017-2402-x
- By:
- Publication type:
- Article
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 7, p. 1225, doi. 10.1007/s00432-017-2359-9
- By:
- Publication type:
- Article
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2015, v. 141, n. 11, p. 2047, doi. 10.1007/s00432-015-1988-0
- By:
- Publication type:
- Article
Erratum to: Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Caspase-Independent Pathway is Related to Nilotinib Cytotoxicity in Cultured Cardiomyocytes.
- Published in:
- Cellular Physiology & Biochemistry (Karger AG), 2017, v. 42, n. 6, p. 2182, doi. 10.1159/000479993
- By:
- Publication type:
- Article
Itrifal-e-Aftimoon potentiates imatinib-induced anti-leukemic effect by influencing FAK/STAT/Akt/ERK signalling pathways against chronic myeloid leukaemia in vitro.
- Published in:
- Journal of Pharmacy & Pharmacology, 2022, v. 74, n. 9, p. 1330, doi. 10.1093/jpp/rgac045
- By:
- Publication type:
- Article
Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling.
- Published in:
- Journal of Pharmacy & Pharmacology, 2017, v. 69, n. 10, p. 1265, doi. 10.1111/jphp.12757
- By:
- Publication type:
- Article
Nilotinib effect on hepatic and renal functions in a sample of Iraqi patients with chronic myeloid leukemia.
- Published in:
- Iraqi Journal of Cancer & Medical Genetics, 2017, v. 10, n. 1, p. 21
- By:
- Publication type:
- Article
CNS demyelination associated with nilotinib.
- Published in:
- Neurological Sciences, 2023, v. 44, n. 9, p. 3335, doi. 10.1007/s10072-023-06827-4
- By:
- Publication type:
- Article
Nilotinib treatment induces cognitive impairment by elevating hippocampal oxidative stress in rats.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2023, v. 27, n. 20, p. 10082
- By:
- Publication type:
- Article
Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2022, v. 26, n. 14, p. 5008
- By:
- Publication type:
- Article
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00917-4
- By:
- Publication type:
- Article
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00891-x
- By:
- Publication type:
- Article
Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-09048-5
- By:
- Publication type:
- Article
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 5, p. 521, doi. 10.1002/cpdd.896
- By:
- Publication type:
- Article
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
- Published in:
- Frontiers in Pharmacology, 2023, v. 14, p. 1, doi. 10.3389/fphar.2023.1154377
- By:
- Publication type:
- Article
National trends in the use of oral chemotherapy over 13 years.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.909948
- By:
- Publication type:
- Article
Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.862504
- By:
- Publication type:
- Article
Nilotinib for the frontline treatment of chronic myeloid leukemia carrying the p230 transcript: dream or reality?
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00017
- By:
- Publication type:
- Article
Effects of an Epithelial Growth Factor Receptor- Tyrosine Kinase Inhibitor Add-on in Stereotactic Radiosurgery for Brain Metastases Originating from Non-Small-Cell Lung Cancer.
- Published in:
- Journal of Korean Neurosurgical Society, 2015, v. 58, n. 3, p. 205, doi. 10.3340/jkns.2015.58.3.205
- By:
- Publication type:
- Article
KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
- Published in:
- American Journal of Clinical Dermatology, 2019, v. 20, n. 3, p. 315, doi. 10.1007/s40257-018-0414-1
- By:
- Publication type:
- Article
Chronic myeloid leukemia‐derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells.
- Published in:
- European Journal of Immunology, 2020, v. 50, n. 4, p. 606, doi. 10.1002/eji.201848051
- By:
- Publication type:
- Article
Structural mechanism of a drug-binding process involving a large conformational change of the protein target.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36956-5
- By:
- Publication type:
- Article
Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 7, p. 1922, doi. 10.3390/pharmaceutics15071922
- By:
- Publication type:
- Article
From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 4, p. 1081, doi. 10.3390/pharmaceutics15041081
- By:
- Publication type:
- Article
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 8, p. 1676, doi. 10.3390/pharmaceutics14081676
- By:
- Publication type:
- Article
Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 6, p. 1216, doi. 10.3390/pharmaceutics14061216
- By:
- Publication type:
- Article
Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 4, p. 529, doi. 10.3390/pharmaceutics13040529
- By:
- Publication type:
- Article
Preparation and Characterization of a Novel Swellable and Floating Gastroretentive Drug Delivery System (sfGRDDS) for Enhanced Oral Bioavailability of Nilotinib.
- Published in:
- Pharmaceutics, 2020, v. 12, n. 2, p. 137, doi. 10.3390/pharmaceutics12020137
- By:
- Publication type:
- Article
Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 10, p. 1361, doi. 10.3390/ph17101361
- By:
- Publication type:
- Article
Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 3, p. 349, doi. 10.3390/ph17030349
- By:
- Publication type:
- Article
Second-Generation Cephalosporins-Associated Drug-Induced Liver Disease: A Study in VigiBase with a Focus on the Elderly.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 5, p. 441, doi. 10.3390/ph14050441
- By:
- Publication type:
- Article
Investigating the potential therapeutic role of targeting STAT3 for overcoming drug resistance by regulating energy metabolism in chronic myeloid leukemia cells.
- Published in:
- Iranian Journal of Basic Medical Sciences, 2022, v. 25, n. 7, p. 904, doi. 10.22038/IJBMS.2022.64138.14121
- By:
- Publication type:
- Article
A case of scurvy associated with nilotinib.
- Published in:
- Journal of Cutaneous Pathology, 2016, v. 43, n. 8, p. 725, doi. 10.1111/cup.12715
- By:
- Publication type:
- Article
Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting.
- Published in:
- American Health & Drug Benefits, 2016, v. 9, p. 16
- By:
- Publication type:
- Article
Designing an Industrially Scalable, Flow-Based Synthesis for the Production of Nilotinib: Chemical Process Modeling and Economic Analysis.
- Published in:
- Columbia Undergraduate Science Journal, 2019, v. 13, p. 21
- By:
- Publication type:
- Article
Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
- Published in:
- Bratislava Medical Journal / Bratislavské Lekárske Listy, 2021, v. 122, n. 8, p. 531, doi. 10.4149/BLL_2021_085
- By:
- Publication type:
- Article
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
- Published in:
- Angewandte Chemie International Edition, 2015, v. 54, n. 30, p. 8717, doi. 10.1002/anie.201501104
- By:
- Publication type:
- Article
c-Abl phosphorylation primes PARIS for neurodegeneration.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Analysis of the binding modes of the first‐ and second‐generation antiandrogens with respect to F876L mutation.
- Published in:
- Chemical Biology & Drug Design, 2021, v. 98, n. 1, p. 60, doi. 10.1111/cbdd.13848
- By:
- Publication type:
- Article
Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 3, p. 2849, doi. 10.3390/ijms24032849
- By:
- Publication type:
- Article